Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Surgical Oncology
Published in: Indian Journal of Surgical Oncology 2/2016

01-06-2016 | Review Article

Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

Authors: Aditi Bhatt, Diane Goéré

Published in: Indian Journal of Surgical Oncology | Issue 2/2016

Login to get access

Abstract

Occurring either synchronously or metachronously to the primary tumor, peritoneal metastases (PM) are diagnosed in 8 to 20 % of the patients with colorectal cancer (CRC). Prognosis of these patients appears to be worse than those with other sites of metastases. While systemic therapy has shown significant prolongation of survival in patients with stage IV colorectal cancer, the outcomes in the subset of patients with PM has been much inferior. Over the last 2 decades, cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) have been effective in substantially prolonging survival in patients with colorectal PM and have the potential to cure certain patients as well. This article reviews the current evidence for CRS and HIPEC to treat colorectal PM as well as future research going on in this form of locoregional treatment.
Literature
1.
Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, De Hingh IH (2011) Predictors and survival of synchronous peritoneal carcinomatoses of colorectal origin: a population-based study. Int J Cancer 128(11):2717–2725CrossRefPubMed
2.
Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89(12):1545–1550CrossRefPubMed
3.
Sadeghi B, Arvieux C, Glehen O, et al. (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88(2):358–363CrossRefPubMed
4.
Zerhouni S, McCart A (2012) Peritoneal carcinomatosis of colorectal origin: Is there a role for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Oncology Exchange 11(2) May 2012
5.
Gustavsson B, Carlsson G, Machover D, Petrelli P, Roth A, Schmoll H, Tveit K, Gibson F (2015) A review of the evolution of systemic chemotherapy in the Management Of Colorectal Cancer. Clin Colorectal Cancer 14(1):1–10CrossRefPubMed
6.
Chua TC, Morris DL, Saxena A, et al. (2011) Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol 18:1560–1567CrossRefPubMed
7.
Sugarbaker PH, VJ v, van tinteren H, SV R, et al. (2004) Re:Toxicity of Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy. J Surg Oncol 88:276–278CrossRefPubMed
8.
Maggiori L, Elias D. (2010) Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol 36 599–603CrossRefPubMed
9.
10.
Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A (2012) Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99:699–705. doi:10.​1002/​bjs.​8679 CrossRefPubMed
11.
Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Pemberton JH, Wolff BG (1992) Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 174:27–32PubMed
12.
Russell AH, Tong D, Dawson LE, Wisbeck WM, Griffin TW, Laramore GE, Luk KH (1983) Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys 1983 Mar 9(3):361–365CrossRefPubMed
13.
Russell AH, Tong D, Dawson LE, Wisbeck W (1984) Adenocarcinoma of the proximal colon. sites of initial dissemination and patterns of recurrence following surgery alone. Cancer 1984 Jan 15 53(2):360–367CrossRefPubMed
14.
Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002 Dec 89(12):1545–1550CrossRefPubMed
15.
Ihemelandu C, Shen P, Stewart J, Votanopoulos K, Levine A (2011) Management Of Peritoneal Carcinomatosis from colorectal cancer. Semin Oncol 2011 August 38(4):568–575CrossRefPubMedPubMedCentral
16.
Esquivel J. (2014) Current Status and Future Directions of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Intervent Oncol 360;2(6):E45-E52
17.
Goldberg RM, Sargent DJ, Morton RF (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMed
18.
Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342CrossRefPubMed
19.
Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008 Apr 20 26(12):2013–2019CrossRefPubMed
20.
Cutsem V, Kohne C, Hitre E, Zaluski J, Chang Chien C, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, Kyung Roh J, Folprecht G, Ruff R, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRefPubMed
21.
Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22 (7): 1535–1546CrossRefPubMed
22.
Franko J, Shi Q, Goldman CD, et al. (2012) Treatment of colorectal peritoneal cacinomatosis with systemic chemotherapy: A pool analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol 30(3):263–267CrossRefPubMedPubMedCentral
23.
Klaver YL, Simkens LH, Lemmens VE, et al. (2012) Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol 38(7):617–623CrossRefPubMed
24.
Koopman M, Antonini NF, Douma J, et al. (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomized control trial. Lancet 370(9582):135–142CrossRefPubMed
25.
Tol J, Koopman M, Rodenburg CJ, et al. (2008) A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO 2 study of the Dutch Colorectal Cancer Group. An interim analysis of toxicity. Ann Oncol 19(4):734–738CrossRefPubMed
26.
Elias D, Lefevre JH, Chevalier J, et al. (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27:681–685CrossRefPubMed
27.
Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980 Feb 40(2):256–260PubMed
28.
Sugarbaker PH, Cunliffe WJ, Beliveau JF, de Bruin E, Graves T (1988) Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treatment 1:66–79
29.
Van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC (1998) Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998 Jan 34(1):148–154CrossRefPubMed
30.
Ceelen WP, Flessner MF (2010) Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 2010 Feb 7(2):108–115CrossRefPubMed
31.
Zoetmulder FA (1996) Cancer cell seeding during abdominal surgery: experimental studies. Cancer Treat Res 82:155–161CrossRefPubMed
32.
Jacquet P, Averbach AM, Jacquet N.(1995) Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Eur J Surg Oncol 1995 Oct;21(5):568–70. Review
33.
Elias D, Di Pietrantonio D, Boulet T, Honore C, Bonnet S, Goere D, Kohneh-Shahri N, Raynard B. (2009) Natural history of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2009 Apr;35(4):434–8. Epub 2008 Mar 28
34.
Sugarbaker PH. (2005) Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal Cancer. Cancer Investig;23(2):155–172CrossRef
35.
Shimizu T, Maeta M, Koga T (1991) Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat. Br J Surg 78(1):57–59CrossRefPubMed
36.
Pelz JO, Doerfer J, Dimmler A, et al. (2006) Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer 6:162CrossRefPubMedPubMedCentral
37.
Mulsow J, Merkel S, Agaimy A, Hohenberger W (2011) Outcomes following surgery for colorectal cancer with synchronous peritoneal metastases. Br J Surg. 2011 Dec 98(12):1785–1791CrossRefPubMed
38.
Matsuda K, Hotta T, Takifuji K, Yamamoto M, Nasu T, Togo N, Oka M, Tabuse K, Yamaue H (2012) Clinical impact of a macroscopically complete resection of colorectal cancer with peritoneal carcinomatosis. Surgery 2012 Feb 151(2):238–244CrossRefPubMed
39.
Désolneux G, Mazière C, Vara J, Brouste V, Fonck M, Béchade D, Bécouarn Y, Evrard S (2015) Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS ONE 2015 Mar 31:10(3)
40.
Cavaliere F, Valle M, De Simone M, et al. (2006) 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S. I. T. I. L. O. multicentric study. In Vivo 20(6 A):747–750PubMed
41.
Elias D, Lefevre JH, Chevalier J, et al. (2008) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27:681–685CrossRefPubMed
42.
Elias D, Gilly F, Boutitie F, Quenet F, Bereder J, Mansvelt B, Lorimier G, D` D, Glehen O (2009) Peritoneal colorectal Carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68CrossRefPubMed
43.
Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ (2010) Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 116:3756–3762. doi:10.​1002/​cncr.​25116 CrossRefPubMed
44.
Verwaal VJ, van Ruth S, de Bree E, et al. (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743CrossRefPubMed
45.
Verwaal VJ, Bruin S, Boot H, et al. (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426–2432CrossRefPubMed
46.
Khatri P. (2009) Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer: A Panacea or Just an Obstacle Course for the Patient? JCO.25.5109
47.
Elias D, Quenet F, Goere D (2012) Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am 21:611–623CrossRefPubMed
48.
Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O, Giovannini M, Lasser P (2004) Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting ran domized trials. Ann Surg Oncol 11:518–521. doi:10.​1245/​ASO.​2004.​09.​008 CrossRefPubMed
49.
Glehen OKF, Sugarbaker PH, Elias D, et al. (2004) Cytoreductive surgery combined with perioperative intraperitonea chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 22:3284–3292CrossRefPubMed
50.
Elias D, Antoun S, Goharin A, Otmany AE, Puizillout JM, Lasser P (2000) Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig 1(5):431–439PubMed
51.
Ortega-Deballon P, Facy O, Jambet S, Magnin G, Cotte E, Beltramo JL, Chauffert B, Rat P (2010) Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann Surg Oncol 2010 Jul 17(7):1957–1963CrossRefPubMed
52.
Sarnaik AA, Sussman JJ, Ahmad SA, McIntyre BC (2007) Lowy AM Technology for the delivery of hyperthermic intraoperative intraperitoneal chemotherapy: a survey of techniques. Recent Results Cancer Res 169:75–82PubMed
53.
Elias D, Bonnay M, Puizillou JM, Antoun S, Dermirdjian S, El Otomany A, et al. (2002) Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Surg Oncol 13:267–272CrossRef
54.
Elias D, Goere D, Blot F, Billard V, Pocard M, Kohneh-Shahri N, Raynard B (2007) Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol 2007 Jun 14(6):1818–1824CrossRefPubMed
55.
Kuzuya T, Yamauchi M, Ito A, et al. (1994) Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol. 46:685–689CrossRefPubMed
56.
Stephens AD, Alderman R, Chang D, et al. (1999) Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6:790–796CrossRefPubMed
57.
Pilati P, Mocellin S, Rossi CR, et al. (2003) Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 10:508–513CrossRefPubMed
58.
Kusamura S, Younan R, Baratti D, et al. (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 106:1144–1153CrossRefPubMed
59.
Franko J, Gusani NJ, Holtzman MP, et al. (2008) Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol 15:3065–3072CrossRefPubMed
60.
Glehen O, Kwiatkowski F, Sugarbaker PH, et al. (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 22:3284–3292CrossRefPubMed
61.
Glockzin G, Ghali N, Lang S, Schlitt H, Piso P (2009) ‘results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal Carcinomatosis from colorectal cancer. J Surg Oncol 100:306–310CrossRefPubMed
62.
Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94:1408–1414CrossRefPubMed
63.
Levine SJH, Russell GB, Geisinger KR, Loggie BL, Shen P (2007) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J. Am. coll. Surg 204(5):943–953CrossRefPubMed
64.
Elias D, Goere D (2007) Peritoneal carcinomatosis of colorectal origin: recent advances and future evolution toward a curative treatment. Recent Results Cancer Res 169:115–122PubMed
65.
Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, François Y, Vignal J, Gilly FN (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003 Oct 10(8):863–869CrossRefPubMed
66.
Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, Steves MA, Sugarbaker PH (1996) Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996 Jun 15 77(12):2622–2629CrossRefPubMed
67.
Hansson J, Graf W, Påhlman L, Nygren P, Mahteme H (2009) Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 2009 Feb 35(2):202–208CrossRefPubMed
68.
Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006 Mar 1 106(5):1144–1153CrossRefPubMed
69.
Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA (2004) Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004 Feb 85(2):61–67CrossRefPubMed
70.
Saxena A, Yan TD, DL. M (2010) A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg 2010 Jan 34(1):70–78CrossRefPubMed
71.
Saxena A, Yan TD, Morris DL (2010) Critical assessment of preoperative and operative risk factors for complications after iterative peritonectomy procedures. Eur J Surg Oncol 2010 Mar 36(3):309–314CrossRefPubMed
72.
Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, Maggiori L, Dumont F, Ducreux M, Elias D (2013) Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 2013 Jun 257(6):1065–1071CrossRefPubMed
73.
Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007 Oct 10 25(29):4575–4580CrossRefPubMed
74.
Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D. (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009 Apr 10;27(11):1829–35. doi: 10.​1200/​JCO.​2008.​19.​9273. Epub 2009 Mar 9
75.
Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, Dumont F, Elias D. (2015) Extent of colorectal peritoneal Carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study. Ann Surg Oncol 2015 Sep;22(9):2958–64. Epub 2015 Jan 29
76.
Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, Maggiori L, Dumont F, Ducreux M, Elias D (2013) Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 2013 Jun 257(6):1065–1071CrossRefPubMed
77.
Esquivel J, Sticca R, Sugarbaker P, et al. (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society Of Surgical Oncology. Ann. surg. Oncologia 14(1):128–133
78.
Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, Dumont F, Elias D.’ (2015) Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study.’ Ann Surg Oncol Jan 29
79.
Maggiori L, Goéré D, Viana B, Tzanis D, Dumont F, Honoré C, Eveno C, Elias D (2013) Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? A case-control study. Ann Surg 2013 Jul 258(1):116–121. doi:10.​1097/​SLA.​0b013e3182778089​ CrossRefPubMed
80.
González-Moreno S (2006 Aug) Peritoneal surface Oncology: A progress report. Eur J Surg Oncol 32(6):593–596
81.
de Bree E, Koops W, Kröger R, van Ruth S, Witkamp AJ (2004) Zoetmulder FA Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 2004 May 1 86(2):64–73CrossRefPubMed
82.
Dromain C, Leboulleux S, Auperin A, Goere D, Malka D, Lumbroso J, Schumberger M, Sigal R, Elias D (2008) Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT Abdominal Imaging 2008 Jan-Feb 33(1):87–93CrossRefPubMed
83.
Elias D, Honoré C, Dumont F, Ducreux M, Boige V, Malka D, Burtin P, Dromain C, Goéré D (2011) Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2011 Aug 254(2):289–293CrossRefPubMed
84.
R. T. Ripley, J. L. Davis, C. D. Kemp, S. M. Steinberg, M. A. Toomey, and I. Avital. (2010) Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. Trials, vol. 11, article no. 62
85.
Sammartino P, Sibio S, Biacchi D, Cardi M, Accarpio F, Mingazzini P, Rosati MS, Cornali T, Di Giorgio A (2012) Prevention of peritoneal metastases from Colon Cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Prac 2012:141585
Metadata
Title
Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer
Authors
Aditi Bhatt
Diane Goéré
Publication date
01-06-2016
Publisher
Springer India
Published in
Indian Journal of Surgical Oncology / Issue 2/2016
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-016-0499-z

Other articles of this Issue 2/2016

Indian Journal of Surgical Oncology 2/2016 Go to the issue

Original Article

The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

DESK OF THE EDITOR

Desk of the Editor

Review Article

Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei

Review Article

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Review Article

Cytoreductive Surgery and Peritonectomy Procedures

Review Article

Preoperative Preparation and Patient Selection for Cytoreductive Surgery and HIPEC